Your email has been added to our waiting list and we will send an invite to you as soon as possible. Thank you for your patience.
In the meantime, if you happen to run a blog, our newly launched Blog Enhancement Suite can utilize the immense power of community to help you get more audience, engagement, content, and revenue with your own embeddable community! It will breathe new life into your blog and can automate many of the tedious tasks that come with the territory, so you can focus more on what matters most... writing.
Help spread the word about Snapzu:
Let others know about Snapzu by tweeting about us. We appreciate every mention!
NIH launches clinical trial of universal influenza vaccine candidate
A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. Healthy participants 18 to 50 years old will receive either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1. Scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID) developed FluMos-v1 to stimulate antibodies against multiple influenza virus strains by displaying part of the influenza virus...